CIRNA | Center for Interdisciplinary Research on Nicotine Addiction

Publications

The Center for Interdisciplinary Research on Nicotine Addiction (CIRNA) continues 10 years of research conducted through the Transdisciplinary Tobacco Use Research Center (TTURC). Below is a list of publications from the TTURC and CIRNA research programs by year.

Year 2013-In Press

Falcone M, Wileyto EP, Ruparel K, Gerraty RT, LaPrate L, Detre JA, Gur R, Loughead J, and Lerman C.  Age-related differences in working memory deficits during nicotine withdrawal.  Addiction Biology, in press (PMID and PMIC in Progress).

Gould TJ, Wilkinson DS, Turner JR, Blendy JA.  Genetic background influences the effects of withdrawal from chronic nicotine on learning and high-affinity nicotinic acetylcholine receptor binding in the dorsal and ventral hippocampus.  Neuropsychopharmacology, 2013; 225(1):201-208 (PMID22836371; PMC in Progress).

Year 2012

Andre JM, Cordero KA, Gould TJ.  Comparison of the performance of DBA/2 and C57BL/6 mice in transitive interference and foreground and background contextual fear conditioning.  Behavioral Neuroscience, 2012; 126(2):249-257 (PMID22309443; PMC3314134; NIHMS347011).

Ashare RL, Ray R, Lerman C, Strasser AA.  Cognitive effects of the acetylcholinesterase inhibitor, donepezil, in healthy, non-treatment seeking smokers: A pilot feasibility study.  Drug and Alcohol Dependence, 2012; 2012; 126(1-2):263-267 (PMID22595038, PMC3424358).

Ashare RL, Tang KZ, Mesaros AC, Blair IA, Leone F, Strasser AA.  Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers.  Journal of Psychoharmacology, 2012; 26(10):1383-1390 (PMID22695488; PMC3526838).

Ashare RL, Karlawish JH, Wileyto EP, Pinto A, Lerman C. APOE ε4, an Alzheimer’s disease susceptibility allele, and smoking cessation.  The Pharmacogenomics Journal, 2012; (Epub ahead of print) (PMID23247396; PMC in Progress).

Cao Y, Featherstone R, Gandal MJ, Liang Y, Jutzeler C, Saunders J, Leitman V, Chen J, Weinberger DR, Lerman C, Siegel SJ.  Nicotine normalizes event related potentials in COMT-Val tg mice and increases g and f spectral density.  Behavioral Neuroscience, 2012; 126(2):332-343 (PMID22309446; PMC in Progress).

Conklin CA, Parzynski CS, Salkeld RP, Perkins KA, Fonte CA. Cue reactivity as a predictor of successful abstinence initiation among adult smokers. Experimental and Clinical Psychopharmacology, 2012; (Epub ahead of print) (PMID:22889039; PMC in Progress).

Falcone M, Gold A, Wileyto EP, Ray R, Ruparel K, Newberg A, Dubroff J, Logan J, Zubieta J-K, Blendy J, Lerman C.  µ-opioid receptor availability in the amygdala is associated with smoking for negative affect relief.  Psychopharmacology, 2012; 222(4):701-708 (PMID22389047; PMC in Progress).

Featherstone RE, Phillips JM, Thieu T, Ehrlichman RS, Halen TB, Leiser SC, Christian E, Johnson E, Lerman C, Siegel SJ.  Nicotine receptor subtype-specific effects on auditory evoked oscilations and potentials.  PLos One, 2012; 7(7):e39775 (PMID2236808; PMC3377164).

Gold AB, Wileyto EP, Lori A, Conti D, Cubells JF, Lerman C.  Pharmacogenetic association of the Galanin Receptor (GALR1) SNP rs2717162 with smoking cessation.  Neuropsychopharmacology, 2012; 37(7):1683-1688 (PMID22290489; PMC3358736).

Gold AB, Lerman C.  Pharmacogenetics of smoking cessation:  Role of nicotine target and metabolism genes.  Human Genetics, 2012; (Epub Ahead of Print) (PMID22290489; PMC in Progress).

Gordiev M, Engstrom PF, Khasanov R, Moroshek A, Sitdikov R, Dgavoronkov V, Schnoll RA. Genetic analysis of polymorphisms in dopamine receptor and transporter genes for association with smoking among cancer patients. European Addiction Research, 2012; 19(2):105-111 (PMID23128675; PMC in Progress).

Gould TJ, Portugal GS, Andre JM, Tadman MP, Marks MJ, Kenney JW, Yildirim E, Adolff M. The duration of nicotine withdrawal-associated deficits in contextual fear conditiioning parallels changes in hippocampal high affinity nicotinic acetylcholine receptor upregulation. Neuropharmacology, 2012; 62(5-6):2118-2125 (PMID22285742; PMC3278577)

Hilario MRF, Turner JR, Blendy JA.  Reward sensitization:  Effects of repeated nicotine exposure and withdrawal in mice.  Neuropsychopharmacology, 2012; 37(12):2661-2670 (PMID22828747; PMC3473332).

Hopkins TJ, Rupprecht LE, Hayes MR, Blendy JA, Schmidt HA.  Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.  Neuropsychopharmacology, 2012; 37(10):2310-2321 (PMID22669169; PMC3422495).

Hussmann GP, Turner JR, Lomazzo E, Venkatesh R, Cousins V, Xiao Y, Yasuda RP, Wolfe BB, Perry DC, Rezvani AH, Levin ED, Blendy JA, Kellar KJ.  Chronic sazetidine-a at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain.  Journal of Experimental Therapeutics, 2012; 343(2):441-450 (PMID22899752; PMC3477215).

Javitz HS, Lerman C, Swan GE.  Comparative dynamics of four smoking withdrawal symptom scales.  Addiction, 2012; 107(8):1501-1511 (PMID 22321019; PMC3394903).

Kenney JW, Raybuck JD, Gould TJ.  Nicotinic receptors in the dorsal and ventral hippocampus differentially modulate contextual fear conditioning.  Hippocampus, 2012; (8):1681-1690 (PMID22271264; PMC3343189).

Kenney JW, Poole RL, Adoff MD, Logue SF, Gould TJ.  Learning and nicotine interact to increase CREB phosphorylation at the jnk1 promoter in the hippocampus.  PLoS ONE, 2012; 7(6):e39939 (PMID2261932; PMC3386232).

Kimmey BK, Rupprecht LE, Hayes MR, Schmidt HD. Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats. Addiction Biology, 2012 (Epub ahead of Print) (PMID23231479; PMC in Progress).

Onksen JL, Briand LA, Galante RJ, Pack AI, Blendy JA.  Running-induced anxiety is dependent on increases in hippocampal neurogenesis.  Genes and Brain Behavior, 2012; 11(5):529-538 (PMID224711438; PMC3389278).

Perkins, KA.  Subjective reactivity to smoking cues as a predictor of quitting success. Nicotine and Tobacco Research, 2012; 14(4):383-387 (PMID22140145; PMC3313783).

Perkins KA, Parzynski CS, Mercincavage M, Conklin CA, Fonte CA, Lerman C. Is self-efficacy for smoking abstinence a cause of, or a reflection on, smoking behavior change?  Experimental and Clinical Psychopharmacology, 2012; 20(1):56-62 (PMID21910550; PMC in Progress).

Perkins KA, Karelitz JL, Jao NC. Optimal carbon monoxide criteria to confirm 24-hr smoking abstinence. Nicotine and Tobacco Research, 2012 (Epub ahead of print) (PMID22990219; PMC in Progress).

Perkins KA, Jao NC, Karelitz JL. Consistency of daily cigarette smoking amount in dependent adults. Psychology of Addictive Behaviors, 2012; (Epub ahead of print) (PMID23088404; PMC in Progress).

Perkins, KA, Karelitz JL, Jao NC, Stratton E. Possible reinforcement enhancing effects of bupropion during initial smoking abstinence. Nicotine and Tobacco Research, 2012; (Epub ahead of Print) (PMID23100457; PMC in Progress).

Portugal GS, Wilkinson DS, Turner JR, Blendy JA, Gould TJ.  Developmental effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. Neurobiology, Learning and Memory. 2012; 97(4):482-494 (PMID22521799; PMC3358528).

Portugal GS, Wilkinson DS, Kenney JW, Sullivan C, Gould TJ.  Strain-dependent effects of acute, chronic, andwithdrawal from chronic nicotine on fear conditioning.  Behavioral Genetics, 2012; 42(1):133-150, (PMID21822688; PMC in Progress).

Schnoll RA, Lerman C, Wileyto P.  Extended duration therapy with transdermal nicotine may attenuate weight gain following smoking cessation.  Addictive Behavior, 2012; 37(4):565-568 (PMID22244706; PMC3288882).

Schnoll RA, Wileyto EP, Leone FT, Tyndale RF, Benowitz NL.  High dose transdermal nicotine for fast metabolizers of nicotine:  A proof of concept placebo-controlled trial.  Nicotine and Tobacco Research, 2012; (Epub ahead of print) (PMID22589423; PMC3545715).

Strasser AA, Tang KZ, Romer D, Jepson C, Cappella JN.  Graphic warning labels in cigarette advertisements improve recall and affect viewing patterns.  American Journal of Preventative Medicine, 2012; 43(1):41-43 (PMID22704744; PMID3377985).

Wileyto EP, Li Y, Chen J, Heitjan DF.  Assessing the fit of parametric cure models.  Biostatistics, 2012 (Epub Ahead of Print) (PMID23197383; PMC in Progress).

Wilkinson DS, Turner JR, Blendy JA, Gould TJ.  Genetic background influences the effects of withdrawal from chronic nicotine on learning and high-affinity nicotinic acetylcholine receptor binding in the dorsal and ventral hippocampus.  Psychopharmacology (Berl), 2012; (Epub Ahead of Print) (PMID2283637; PMC in Progress).

Year 2011

Andre JM, Leach PT, Gould TJ. Nicotine ameliorates NMDA receptor antagonist-induced deficits in contextual fear conditioning through high-affinity nicotine acetylcholine receptors in the hippocampus. Neuropharmacology, 2011; 60(4):617-625 (PMID21167848; PMC3031743; NIHMS263276).

Audrain-McGovern J, Benowitz NL.  Cigarette smoking, nicotine, and body weight.  Clinical Pharmacology and Therapeutics, 2011; 90(1):164-168 (PMICD21633341; PMC3195407; NIHMS326984).

Blendy JA. Modeling neuropsychiatric disease-relevant human SNPs in mice. Neuropsychopharmacology, 2011; 36(1):364-365 (PMID21116258; PMC3055505).

Falcone M, Jepson C, Benowitz N, Bergen AW, Pinto A, Wileyto EP, Baldwin D, Tyndale R, Lerman C, Ray R.  Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokers.  Nicotine and Tobacco Research, 13(6):498-503, 2011 (PMID21385908; PMC3103715).

Falcone M, Jepson C, Sanborn P, Cappella JN, Lerman C, Strasser AA. Association of BDNF and COMT genotypes with cognitive processing of anti-smoking PSAs.  Genes and Brain Behavior, 2011; 10(8):862-867 (PMID21883922; PMC in Progress).

Gould TJ. Addiction and cognition.  Addiction Science and Clinical Practice, 2011; 5:4-15 (PMID22002448; PMC3120118).

Javitz HS, Swan GE, Lerman C.  The dynamics of the urge-to-smoke following smoking cessation via pharmacotherapy.  Addiction, 2011; 106(10):1835-1845 (PMID21561501; PMC in Progress).

Kenney JW, Adoff MD, Wilkinson DS, Gould TJ.  The effects of acute, chronic and withdrawal from chronic nicotine on novel and spatial object recognition in male C57BL/6J Mice. Psychopharmacology, 2011; 217(3):353-365 (PMID21487656; PMC3161157; NIHMS296241).

King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, Kaprio J, Lerman C, Park PW.  Smoking cessation pharmacogenetics:  analysis of varenicline and buproprion in placebo-controlled clinical trials.  Neuropsychopharmacology, 37(3):641-650 (PMID22048466; PMC3260990).

Lee DC, Perkins KA, Zimmerman E, Robbins G, Kelly TH.  Effects of 24 hours of tobacco withdrawal and subsequent tobacco smoking among low and high sensation seekers.  Nicotine and Tobacco Research, 2011; 13(10):943-954 (PMID21690318; PMC3179670).

Lee S, Capella JN, Lerman C, Strasser AA.  Smoking cues, argument strength, and perceived effectiveness of antismoking PSAs.  Nicotine and Tobacco Research, 2011; 13(4):282-290 (PMID21330273; PMC3066405).

Lee W, Bergen AW, Swan GE, Li D, Liu J, Thomas P, Tyndale R, Benowitz NL, Lerman C, Conti DV.  Gender stratified gene and gene-treatment interactions in smoking cessation.  The Pharmacogenomics Journal, 2011; Epub ahead of print (PMID21808284; NIHMS305090; PMC3208134).

Lerman, C.  Preclinical data elucidate molecular and neural mechanisms of perinatal nicotine effects on neurodevelopment and behavior: Translational opportunities and implications.  Neuropsychopharmacology, 2011; 35(12):2322-2323 ( PMID20948511; PMC3055325).

Li YM, Wileyto EP, Heitjan DF. Statistical analysis of daily smoking status in smoking cessation clinical trials. Addiction, 2011; 106(11):2039-2046 (PMID21631623; PMC3197211; NIHMS313977).

Loughead J, Ray R, Wileyto EP, Ruparel K, O’Donnell GP, Senecal N, Siegel S, Gur RC, Lerman C.  Brain activity and emotional processing in smokers treated with varenicline.  Addiction Biology, 2011, Epub ahead of print (PMID21507156; PMC in Progress).

Mrazek DA, Lerman C.  Facilitating clinical implementation of pharmacogenomics.  Journal of the American Medical Association, 2011; 306(3):304-305 (PMID2177199; PMC in Progress).

Onksen JL, Brown EJ, Blendy JA.   Selective deletion of a cell cycle checkpoint kinase (ATR) reduces neurogenesis and alters responses in rodent models of behavioral affect.  Neuropsychopharmacology, 2011; 36(5):960-969.  (PMID21248719; PMC3077265; NIHMS255774).

Perkins KA, Lerman C.  Early human screening of medications to treat drug addiction: novel paradigms and the relevance of pharmacogenetics.  Clinical Pharmacology and Therapeutics, 2011; 89(3):460-463 (PMID21270792; PMC3188428; NIHMS326880).

Portugal GS, Wilkinson DS, Kenney JW, Sullivan C, Gould TJ.  Strain-dependent effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning.  Behavioral Genetics, 2011; 42(1):133-150 (PMID21822688; PMC in Progress).

Ray R, Ruparel K, Newberg A, Wileyto E., Loughead J, Divgi C, Blendy JA, Logan J, Zubieta JK, Lerman C.  Human mu opioid receptor (OPRM1 A118G) polymorphism is associated with brain mu opiod receptor binding potential in smokers.  Proceedings of the National Academy of Sciences USA, 2011; 108(22):9268-9273 (PMID21576462; PMC3107291).

Scholll RA, Martinez E, Tatum KL, Glass M, Bernath A, Ferris D, Reynolds P.  Increased self-efficacy to quit and perceived control over withdrawal symptoms predict smoking cessation following nicotine dependence treatment. Addictive Behavior, 2011; 36(1-2):144-147 (PMID20869812; PMC2981675; NIHMS232731).

Schnoll RA and Shields AE. Physician barriers to incorporating pharmacogenetic treatment strategies for nicotine dependence into clinical practice. Clinical Pharmacology and Therapeutics, 2011; 89(3) 345-347 (PMID21326262; PMC3184286; NIHMS326995).

Schnoll RA, Cappella J, Lerman C, Pinto A, Patterson F, Wileyto P, Bigman C, and Leone F. A novel recruitment message to increase enrollment into a smoking cessation treatment program: Preliminary results from a randomized trial. Health Communication, 2011; 26(8):735-742 (PMID21667366; PMC in Progress).

Schnoll RA, Leone F.  Biomarkers to optimize the treatment of nicotine dependence.  Biomarkers Medicine, 2011; 5(6):745-761 (PMC22103610; PMC3285251; NIHMS356712).

Strasser AA, Benowitz NL, Pinto A, Tang KZ, Hecht SS, Carmella SG, Tyndale RF, Lerman C.  Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level.  Cancer Epidemiology, Biomarkers & Prevention, 2011; 20(2):234-238 (PMID21212060; PMC3077576; NIHMS260488).

Strasser AA, Orom H, Tang KZ, Dumont RL, Cappella JN, Kozlowski LT.  Graphic-enhanced information improves perceived risks of cigar smoking.  Addictive Behaviors, 2011; 36(8):865-869 (PMID21481542; PMC3094503; NIHMS288687).

Turner JR, Castellano LM, Blendy JA. Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline. Nicotine and Tobacco Research, 2011; 13(1):41-46 (PMID21097981; PMC3001959).

Turner JR, Ortinski PI, Sherrard RM, Kellar KJ. Cerebella nicotinic cholinergic receptors are intrinsic to the cerebellum: implications for diverse functional roles.  Cerebellum, 2011; 10(4):748-757 (PMID21562921; PMC in Progress).

Wilkinson DS, Gould TJ.  The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice.  Behavioural Brain Research, 2011; 223(1):53-57 (PMID21514327; PMC3111856).

Year 2010

Briand LA, Blendy JA. Molecular and genetic substrates linking stress and addiction. Brain Research, 2010; 1314:219-234 (PMID19900417; PMC2819611; NIHMS158207).

Briand LA, Vassoler FM, Pierce RC, Valentino RJ, Blendy JA. Ventral tegmental afferents in stress-induced reinstatement: the role of cAMP response element-binding protein. Journal of Neuroscience, 2010; 30(48):16149-16159 (PMID21123561; PMC3075606; NIHMS255165).

Furberg H, Ostroff J, Lerman C, Sullivan PF.  The public health utility of genome-wide association study results for smoking behavior.  Genome Medicine, 2010; 2(4)26 (PMID20423533; PMC2873804).

Gould, TJ.Addiction and cognition.  Addiction Science & Clinical Practice, 2010; 5(2):4-14 (PMC in Progress).

Leader AE, Lerman C, Cappella JN.  Nicotine vaccines:  Will smokers take a shot at quitting?  Nicotine and Tobacco Research, 2010; 12(4):390-397 (PMID20185516; PMC2847077).

Lerman C, Audrain-McGovern J. Reinforcing effects of smoking: more than a feeling. Biological Psychiatry, 2010; 67(8):699-701 (PMID20362220; PMC2857778; NIHMS186882).

Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, Benowitz N, Tyndale RF.Genetic variation in nicotine metabolism predicts the efficacy of extended duration transdermal nicotine therapy.Clinical Pharmacology and Therapeutics, 2010; 87(5):553-557 (PMID20336063; PMC in Progress).

Lerman C. Preclinical data elucidate molecular and neural mechanisms of perinatal nicotine effects on neurodevelopment and behavior: translational opportunities and implications. Neuropsychopharmacology, 2010; 35 (12):2322-2323 (PMID20948511; PMC3055325).

Li Y, Wileyto EP, Heitjan DF.Modeling smoking cessation data with alternating states and a cure fraction using frailty models.Statistics in Medicine, 2010; 29(6):627-638 (PMID20077505; PMC in Progress).

Loughead J, Ray R, Wileyto EP, Ruparel K, Sanborn P, Siegel S, Gur RC, Lerman, C.Effects of the a4b2 partial agonist varenicline on brain activity and working memory in abstinent smokers.Biological Psychiatry, 2010; 67(8):715-721 (PMID20207347; PMC in Progress).

Mague SD, Blendy JA.OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.Drug and Alcohol Dependence, 2010; 108(3):172-182 (PMID20074870; PMC2887703; NIHMS206521).

Morgan G, Backinger C, Lerman C, Vocci F. Translational medication development for nicotine addiction. American Journal of Health Behavior, 2010; 34(3):267-274 (PMID20001184; PMC in Progress).

Patterson F, Jepson C, Loughead J, Perkins K, Strasser AA, Siegel S, Frey J, Gur R, Lerman C.Working memory deficits predict short-term smoking resumption following brief abstinence.Drug and Alcohol Dependence, 2010; 106:61-64 (PMID19733449; PMC2815089; NIHMS140390).

Perkins KA, Karelitz JL, Conklin CA, Sayette MA, Giedgowd GE.Acute negative affect relief from smoking depends on the affect situation and measure but not on nicotine. Biological Psychiatry, 2010; 67(8):707-714 (PMID20132927; PMC in Progress).

Perkins KA, Mercincavage M, Fonte C, Lerman C. Varenicline’s effects on acute smoking behavior and reward and their association with subsequent abstinence. Psychopharmacology, 2010; 210(1):45-51 (PMID20306175; PMC2863002; NIHMS193879).

Perkins KA, Lerman C, Fonte CA, Mercincavage M, Stitzer ML, Chengappa KNR, Jain A. Cross-validation of a new procedure for early screening of smoking cessation medications in humans. Clinical Pharmacology and Therapeutics, 2010; 88(1):109-114 (PMID20485335; PMC in Progress).

Raybuck JD, Gould, TJ.  The role of nicotinic acetylcholine receptors in the medial prefrontal cortex and hippocampus in trace fear conditioning.  Neurobiology of Learning and Memory, 2010; 94(3):353-363 (PMID20727979; PMC2949463; NIHMS230848).

Ray R, Mitra N, Baldwin D, Guo M, Patterson F, Heitjan DJ, Jepson C, Wileyto EP, Wei J, Payne T., Ma JZ, Li MD, Lerman C.Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. Neuropsychopharmacology, 2010; 35(6):1374-1382 (PMID20147892; PMC2855736; NIHMS168784).

Rudnick N, Strasser A, Phillips J, Jepson C, Patterson F, Frey J, Turetsky B, Lerman C, Siegel S.Mouse model predicts effects of smoking and varenicline on event-related potentials in humans.Nicotine and Tobacco Research, 2010; 12(6):589-597 (PMID20395358, PMC2878727).

Schnoll RA, Patterson F, Wileyto EP, Heitjan D, Shields AE, Asch D, Lerman C. Effectiveness of extended duration transdermal nicotine therapy: a randomized trial.Annals of Internal Medicine, 2010; 152(3):144-151 (PMID20124230; PMC in Progress).

Schnoll RA, Martinez E, Tatum KL, Weber DM, Kuzla N, Glass M, Ridge JA, Langer C, Miyamoto C, Leone F. A bupropion smoking cessation clinical trial for cancer patients. Cancer Causes and Control, 2010; 21(6):811-820 (PMID20087643; PMC in Progress).

Schnoll RA, Martinez E, Tatum KL, Glass M, Bernarth A, Ferris D, Reynolds P. Nicotine patch vs. nicotine lozenge for smoking cessation: An effectiveness trial coordinated by the Community Clinical Oncology Program. Drug and Alcohol Dependence, 2010; 107(2-3):237-243 (PMID20004065; PMC2834192; NIHMS182069).

The Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior.  Nature Genetics, 42(5):441-447 (PMID20418890; PMC2914600; NIHMS222027).

Turner JR, Castellano LM, Blendy JA. Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior. Journal of Pharmacological Experimental Therapy, 2010; 334(2):665-672 (PMID20435920; PMC2913767).

Wei J, Ma JZ, Payne TJ, Cui W, Ray R, Mitra N, Lerman C, Li MD.Replication and extension of association of choline acetyltransferase (ChAT) with nicotine dependence in European and African American smokers.Human Genetics, 2010; 127(6):691-698 (PMID20383528; PMC in Progress).

Year 2009

Audrain-McGovern J, Rodriguez D, Epstein LH, Cuevas J, Rodgers K, Wileyto EP.Does delay discounting play an etiological role in smoking or is it a consequence to smoking?Drug and Alcohol Dependence, 2009; 103(3):99-106 (PMID19443136; PMC2743449; NIHMS129339).

Audrain-McGovern J, Rodriguez D, Cuevas J, Rodgers K.The role of depression in adolescent smoking trajectories. Journal of Dual Diagnosis, 2009; 5(2):179-190.

Audrain-McGovern J, Rodriguez D, Kassel JD. Adolescent smoking and depression: evidence of self-medication and peer smoking mediation. Addiction, 2009; 104(10):1743-1756 (PMID19549056).

Audrain-McGovern J, Rodriguez D, Epstein LH, Rodgers K, Cuevas J, Wileyto EP.Young adult smoking: what factors differentiate ex-smokers, smoking cessation treatment seekers and nontreatment seekers? Addictive Behaviors, 2009; 34(12):1036-1041 (PMID19619948; NIHMS117061).

Baker TB, Cummings KM, Hatsukami DK, Johnson CA, Lerman C, Niaura R, O’Malley SS.Transdisciplinary Tobacco Use Research Centers: research achievements and future implications.Nicotine and Tobacco Research, 2009; 11(10):1231-1244 (PMID19633277; PMC2746833).

Bergen AW, Conti DV, Van Den Berg D, Lee W, Liu J, Li D, Guo N, Mi H, Thomas PD, Allen F, Lessov-Schlaggar CN, Krasnow R, He Y, Nishita D, Jiang R, McClure JB, Tildesley E, Hops H, Tyndale RF, Benowitz NL, Lerman C, Swan G.E. Dopamine genes and nicotine dependence in treatment seeking and community smokers. Neuropsychopharmacology, 2009; 34(10):2252-2264 (PMID19494806; NIHMS113167).

Bodarky CL, Halene TB, Ehrlichman RS,Banerjee A, Ray R, Hahn CG, Jonak G, Siegel SJ.Novel environment and GABA agonists alter event-related potentials in N-methyl-D-aspartate NR1 hypomorphic and wild-type mice. The Journal of Pharmacology and Experimental Therapeutics, 2009; 331(1):308-318 (PMID19602553; PMC2766227).

Dahm JL, Cook E, Baugh K, Wileyto EP, Pinto A, Leone F, Halbert CH, Schnoll RA. Predictors of enrollment in a smoking cessation clinical trial after eligibility screening. Journal of the National Medical Association, 2009; 101(5):450-455 (PMID19476198).

Ding W, Lehrer SF, Rosenquist JN, Audrain-McGovern J.The impact of poor health on academic performance: new evidence using genetic markers. Journal of Health Economics, 2009; 28(3):578-597 (PMID19217678).

Griffith SD, Shiffman S, Heitjan DF. A method comparison study of timeline followback and ecological momentary assessment of daily cigarette consumption. Nicotine and Tobacco Research, 2009; 11(11):1368-1373 (PMID19808861; PMC2762933).

Isiegas C, Mague SD, Blendy JA.Sex differences in response to nicotine in C57Bl/6:129SvEv mice.Nicotine and Tobacco Research, 2009; 11(7):851-858 (PMID19483179; PMC2699930).

Kang Y, Cappella JN, Lerman C, Strasser AA.The effect of smoking cues in antismoking advertisements on smoking urge and psychophysiological reactions.Nicotine and Tobacco Research, 2009; 11(3):254-261 (PMID19251767; PMC2666377).

Langleben DD, Loughead JW, Ruparel K, Hakun JG, Busch-Winokur S, Holloway MB, Strasser AA, Cappella JN, Lerman C.Reduced prefrontal and temporal processing and recall of high “sensation value” ads.Neuroimage, 2009; 46(1):219-225 (PMID19457412; NIHMS183449).

Lerman C, Perkins KA, Gould T. Nicotine dependence endophenotypes in chronic smokers. National Cancer Institute, Phenotypes and Endophenotypes: Foundations for Genetic Studies of Nicotine Use and Dependence, Tobacco Control Monograph No. 20. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. NIH Publication No. 08-6366, 2009.

Loughead J, Wileyto EP, Valdez JN, Sanborn P, Tang K, Strasser AA, Ruparel K, Ray R, Gur RC, Lerman C.Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype.Molecular Psychiatry, 2009; 14(8):820-826 (PMID19065145).

Mague SD, Isiegas C, Huang P, Liu-Chen L-Y, Lerman C, Blendy JA.Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proceedings of the National Academy of Sciences USA, 2009; 106(26):10847-10852 (PMID19528658; PMC2705603).

Newberg AB, Ray R, Scheuermann J, Wintering N, Saffer J, Schmitz A, Freifelder R, Karp J, Lerman C, Divgi C.Dosimetry of [11C] Carfentanil, a μ-Opioid receptor imaging agent. Nuclear Medicine Communications, 2009; 30(4):314-318 (PMID19242386; NIHMS111102).

Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC, Frey JM, Siegel S, Lerman C.Varenicline improves mood and cognition during smoking abstinence.Biological Psychiatry, 2009; 65(2):144-149 (PMID18842256; PMC2615779; NIHMS85559).

Perkins KA, Coddington SB, Karelitz JL, Jetton C, Scott JA, Wilson AS, Lerman C.Variability in initial nicotine sensitivity due to sex, history of other drug use, and parental smoking.Drug and Alcohol Dependence, 2009; 99(1-3):47-57 (PMID18775605; PMC2648532; NIHMS90482).

Perkins KA, Briski J, Fonte C, Scott J, Lerman C.Severity of tobacco abstinence symptoms varies by time of day.Nicotine and Tobacco Research, 2009; 11(1):84-91 (PMID19246445; PMC2734287).

Perkins KA, Grottenthaler A, Ciccocioppo MM, Conklin CA, Sayette MA, Wilson AS.Mood, nicotine, and dose expectancy effects on acute responses to nicotine spray. Nicotine and Tobacco Research, 2009; 11(5):540-546 (PMID19351782; PMC2671464).

Perkins KA.Acute responses to nicotine and smoking: implications for prevention and treatment of smoking in lower SES women.Drug and Alcohol Dependence, 2009; 104(Suppl 1):S79-S86 (PMID19084357).

Perkins KA, Lerman C, Mercincavage M, Fonte CA, Briski JL.Nicotinic acetylcholine receptor b2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch.Cancer Epidemiology, Biomarkers & Prevention, 2009; 18(10):2608-2612 (PMID19755656; PMC2759850; NIHMS135376).

Portugal GS, Gould TJ.Nicotine withdrawal disrupts new contextual learning.Pharmacology, Biochemistry and Behavior, 2009; 92(1):117-123 (PMID19028516; PMC2777668; NIHMS110747).

Ray R., Rukstalis M, Jepson C, Strasser A, Patterson F, Siegel S, Lerman C.Effects of atomoxetine on subjective and neurocognitive symptoms of nicotine abstinence., Journal of Psychopharmacology, 2009; 23:168-176 (PMID18515446).

Ray R, Tyndale, RF, Lerman, C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes.Journal of Neurogenetics, 2009; 23(3):252-261 (PMID19169923).

Ray R, Schnoll RA, Lerman C.Nicotine dependence: biology, behavior, and treatment.Annual Reviews of Medicine, 2009; 60:247-260 (PMID19630572).

Raybuck JD, Gould TJ. Nicotine withdrawal-induced deficits in trace fear conditioning in C57BL/6 mice - a role for high-affinity b2 subunit-containing nicotinic acetylcholine receptors.European Journal of Neuroscience, 2009; 29:377-387 (PMID19200240; PMC2746945; NIHMS138587).

Rudnick, ND, Koehler, C., Picciotto, MR, Siegel, SJ. Role of beta2-containing nicotinic acetylcholine receptors in auditory event-related potentials. Psychopharmacology, 2009; 202:745-751 (PMID18931833).

Saccone SF, Bierut LJ, Chesler EJ, Kalivas PW, Lerman C, Saccone NL, Uhl GR, Li CY, Philip VM, Edenberg HJ, Sherry ST, Feolo M, Moyzis RK, Rutter JL.Supplementing high-density SNP microarrays for additional coverage of disease-related genes: addiction as a paradigm. PLoS ONE, 2009; 4(4):e5525 (PMID19381300; PMC2668711).

Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C.Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study.Pharmacology, Biochemistry and Behavior, 2009; 92:6-11 (PMID19000709).

Stepanov I, Carmella SG, Han S, Pinto A, Strasser AA, Lerman C, Hecht SS.Evidence for endogenous formation of Nt-nitrosonornicotine in some long term nicotine patch users.Nicotine and Tobacco Research, 2009; 11(1):99-105 (PMID19246447, PMC2734288).

Strasser AA, Cappella JN, Jepson C, Fishbein M, Tang KZ, Han E, Lerman C.Experimental evaluation of antitobacco PSAs: effects of message content and format on physiological and behavioral outcomes.Nicotine and Tobacco Research, 2009; 11(3):293-302 (PMID19246628; PMC2666374).

Thomas PD, Mi H, Swan GE, Lerman C, Benowitz N, Tyndale RF, Bergen AW, Conti DV.A systems biology network model for genetic association studies of nicotine addiction and treatment.Pharmacogenetics and Genomics, 2009; 19(7):538-551 (PMID19525886).

Year 2008

Amann LC, Phillips JM, Halene TB, Siegel SJ. Male and female mice differ for baseline and nicotine-induced event related potentials. Behavioral Neuroscience, 2008; 122(5):982-990.

Andre JM, Gulick D, Portugal GS, Gould TJ. Nicotine withdrawal disrupts both foreground and background contextual fear conditioning but not pre-pulse inhibition of the acoustic startle response in C57BL/6 mice. Behavioural Brain Research, 2008; 190(2)174-181.

Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD, Bergen AW, Swan GE, Tyndale RF, Benowitz NL, Lerman, C. Nicotinic acetylcholine receptor b2 implicated in a pathway-based candidate gene study of smoking cessation. Human Molecular Genetics, 2008; 17(18):2834-2848.

David SP, Johnstone EC, Murphy MF, Aveyard P, Guo B, Lerman C, Munafo MR. Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analysis. Drug and Alcohol Dependence, 2008; 98(1-2):77-85.

Davis JA, Gould TJ. Associative learning, the hippocampus, and nicotine addiction. Current Drug Abuse Reviews, 2008; 1:9-19.

Furberg H, Lichtenstein P, Pederson NL, Bulik C, Lerman C, Sullivan PF. Snus use and other correlates of smoking cessation in the Swedish twin registry. Psychological Medicine, 2008; (38):1299-1308.

Furberg H, Lichtenstein P, Pedersen NL, Thornton L, Bulik CM, Lerman C, Sullivan PF. The STAGE cohort: a prospective study of tobacco use among Swedish twins. Nicotine and Tobacco Research, 2008; 10(12):1727-1735.

Gulick D, Gould TJ. Varenicline ameliorates ethanol-induced deficits in learning in C57BL/6 mice. Neurobiology of Learning and Memory, 2008; 90(1):230-236.

Heitjan DF, Guo M, Ray R, Wileyto EP, Epstein LH, Lerman C. Identification of pharmacogenetic markers in smoking cessation therapy. American Journal of Medical Genetics Neuropsychiatric Genetics, 2008; 147B(6):712-719.

Heitjan DF, Asch DA, Ray R, Rukstalis M, Patterson F, Lerman C. Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. The Pharmacogenomics Journal, 2008; 8(6):391-399.

Kenney JW, Gould TJ. Nicotine enhances context learning but not context-shock associative learning. Behavioral Neuroscience, 2008; 38(1):1158-1165.

Patterson F, Kerrin K, Wileyto EP, Lerman C. Increase in anger symptoms predicts relapse in a smoking cessation trial. Drug and Alcohol Dependence, 2008; 95(1-2):173-176.

Patterson F, Schnoll R, Wileyto EP, Pinto A, Epstein L, Shields PG, Hawk LW, Tyndale, RF, Benowitz N, Lerman C. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clinical Pharmacology and Therapeutics, 2008; 84:320-328.

Perkins KA, Lerman C, Coddington S, Karelitz JL. Association of retrospective early smoking experiences with prospective sensitivity to nicotine via nasal spray in nonsmokers. Nicotine and Tobacco Research, 2008; 10(8):1335-1345.

Perkins KA, Lerman C, Stitzer M, Fonte CA, Briski JL, Scott JA, Chengappa KN. Development of procedures for early screening of smoking cessation medications in humans. Clinical Pharmacology and Therapeutics, 2008; 84(2):216-221.

Perkins, KA, Lerman C, Coddington S, Jetton C, Karelitz JL, Wilson A, Jennings JR, Ferrell R, Bergen AW, Benowitz NL. Gene and gene by sex associations with initial sensitivity to nicotine in nonsmokers. Behavioural Pharmacology, 2008; 19(5-6):630-640.

Perkins KA, Lerman C, Grottenthaler A, Ciccocioppo MM, Milanak M, Conklin CA, Bergen AW, Benowitz NL. Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behavioural Pharmacology, 2008; 19(5-6):641-649.

Perkins KA, Lerman C, Coddington SB, Jetton C, Karelitz JL, Scott JA, Wilson AS. Initial nicotine sensitivity in humans as a function of impulsivity. Psychopharmacology, 2008; 200(4):529-544.

Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine and Tobacco Research, 2008; 10(7):1245-1250.

Piper ME, McCarthy DE, Bolt DM, Smith SS, Lerman C, Benowitz N, Fiore MC, Baker TB. Assessing dimensions of nicotine dependence: an evaluation of the Nicotine Dependence Syndrome Scale (NDSS) and the Wisconsin Inventory of Smoking Dependence Motives (WISDM). Nicotine and Tobacco Research, 2008; 10(6):1009-1020.

Portugal GS, Kenney JW, Gould TJ. Beta2 subunit containing acetylcholine receptors mediate nicotine withdrawal deficits in the acquisition of contextual fear conditioning. Neurobiology of Learning and Memory, 2008; 89(2):106-113.

Portugal GS, Gould TJ. Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: converging evidence from human and animal research. Behavioural Brain Research, 2008; 193(1)1-16.

Ray R, Loughead J, Wang Z, Detre J, Yang E, Gur R, Lerman C. Neuroimaging, genetics and the treatment of nicotine addiction. Behavioural Brain Research, 2008; 193(2):159-169.

Raybuck JD, Portugal GS, Lerman C, Gould TJ. Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice. Behavioral Neuroscience, 2008; 12(5):1166-1171.

Schnoll RA, Epstein L, Audrain J, Niaura R, Hawk L, Shields P, Lerman C, Wileyto EP. Can the blind see? Participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation. Journal of Substance Abuse Treatment, 2008; 34(2):234-241.

Schnoll RA, Wileyto EP, Pinto A, Leone F, Gariti P, Siegel S, Perkins KA, Dackis C, Heitjan DF, Berrettini W, Lerman C. A placebo-controlled trial of modafinil for nicotine dependence. Drug and Alcohol Dependence, 2008; 98(1-2):86-93.

Shields AE, Levy DE, Blumenthal D, Currivan D, McGinn-Shapiro M, Weiss KB, Yucel R, Lerman C. Primary care physicians’ willingness to offer a new genetic test to tailor smoking treatment, according to test characteristics. Nicotine and Tobacco Research, 2008; 10(6):1037-1045.

Shields AE, Lerman C. Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready? Clinical Pharmacology and Therapeutics, 2008; 83(4):635-639.

Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, David SP, Niaura R, Lerman C. Molecular genetics of successful smoking cessation: convergent genome-wide association results. Archives of General Psychiatry, 2008; 65(6):683-693.

Wang Z, Ray R, Faith M, Tang K, Wileyto EP, Detre JA, Lerman C. Nicotine abstinence-induced cerebral blood flow changes by genotype. Neuroscience Letters, 2008; 438(3):275-280.

Wang H, Heitjan DF. Modeling heaping in self-reported cigarette counts. Statistics in Medicine, 2008; 27:3789-3804.

Year 2007

Audrain-McGovern J, Halbert CH, Rodriguez D, Epstein LH, Tercyak KP. Predictors of participation in a smoking cessation program among young adult smokers. Cancer Epidemiology, Biomarkers and Prevention, 2007; 16:617-619.

Audrain-McGovern J, Al Koudsi N, Rodriguez D, Wileyto EP, Shields PG, Tyndale RF. The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics, 2007; 119(1):264-274.

Baker TB, Piper ME, McCarthy DE, Bolt DM, Smith SS, Kim S-Y, Colby S, Conti D, Giovino GA, Hatsukami D, Hyland A, Krishnan-Sarin S, Niaura R, Perkins KA, Toll BA. Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. Nicotine and Tobacco Research, 2007, 9 (suppl. 4); S555-S570.

Berrettini WH, Wileyto EP, Epstein L, Restine S, Hawk L, Shields P, Niaura R, Lerman C. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biological Psychiatry, 2007; 61(1):111-118).

David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafo MR, Shields PG, Lerman C, Strong D, McCaffery J, Niaura R. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine and Tobacco Research, 2007; 9(8):821-833.

David SP, Strong DR, Munafò MR, Brown RA, Lloyd-Richardson EE, Wileyto EP, Evins AE, Shields PG, Lerman C, Niaura R. Bupropion efficacy for smoking cessation is influenced by the DRD2 TaqlA polymorphism: analysis of pooled data from two clinical trials. Nicotine and Tobacco Research, 2007; 9(12):1251-1257.

Davis JA, Kenney JW, Gould TJ. Hippocampal alpha4beta2 nicotinic acetylcholine receptor involvement in the enhancing effect of acute nicotine on contextual fear conditioning. The Journal of Neuroscience, 2007; 27(40):10870-10877.

Davis JA, Gould TJ. Beta2 subunit-containing nicotinic receptors mediate the enhancing effect of nicotine on trace cued fear conditioning in C57BL/6 mice. Psychopharmacology, 2007; 190(3):343-352.

Davis JA, Gould TJ. Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning. Neuropsychopharmacology, 2007; 32(9):2011-2019.

Hutchison KE, Allen D, Haughey H, Jepson C, Lerman C, Benowitz N, Stitzel J, Bryan A, Filbey F. CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Archives of General Psychiatry, 2007; 64(9):1078-1086.

Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk L, Lerman C, Tyndale R. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biological Psychology, 2007; 62(6):635-641.

Lee AM, Jepson C, Shields PG, Benowitz N, Lerman C, Tyndale RF. CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer Epidemiology, Biomarkers and Prevention, 2007; 16(6):1312-1314.

Lerman C, Schnoll RA, Munafò M. Genetics and smoking cessation: improving outcomes in smokers at risk. American Journal of Preventive Medicine, 2007; 33(6 Suppl.):S398-405.

Lerman C, LeSage MG, Perkins KA, O’Malley SS, Siegel SJ, Benowitz NL, Corrigall WA. Translational research in medication development for nicotine dependence. Nature Reviews Drug Discovery, 2007; 6(9):746-762.

Leventhal AM, Waters AJ, Boyd S, Moolchan ET, Lerman C, Pickworth WB. Gender differences in acute tobacco withdrawal: effects on subjective, cognitive, and physiological measures. Experimental and Clinical Psychopharmacology, 2007; 15(1):21-36.

Leventhal AM, Waters AJ, Boyd S, Moolchan ET, Heishman SJ, Lerman C, Pickworth WB. Associations between Cloniger’s temperament dimensions and acute tobacco withdrawal. Addictive Behaviors, 2007; 32(12):2976-2989.

Metzger, KL, Maxwell CR, Liang Y, Siegel SJ. Effects of nicotine vary across two auditory evoked potentials in the mouse. Biological Psychiatry, 2007; 61(1) 23-30.

Newberg A, Lerman C, Wintering N, Ploessl K, Mozley PD. Dopamine transporter binding in smokers and nonsmokers. Clinical Nuclear Medicine, 2007; 32(6):452-455.

Park ER, Kleimann S, Pelan JA, Shield, AE. Anticipating clinical integration of genetically-tailored tobacco dependence treatment: perspectives of primary care physicians. Nicotine and Tobacco Research, 2007; 9(2):271-279.

Phillips JM, Ehrlichman RS, Siegel SJ. Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma. Neuroscience, 2007; 144(4):1314‑1323.

Phillips JM, Siegel SJ, Shields AE, Patterson F, Gould TJ, Strasser AA, Ray R, Pinto A, Audrain-McGovern J, Rukstalis M, Perkins KA, Blendy JA, Lerman C. Translating basic science to improve pharmacotherapy for nicotine dependence. Nicotine and Tobacco Research, 2007; 9(Suppl.4):S583-S598.

Portugal G, Gould TJ. Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning. Pharmacology, Biochemistry, and Behavior, 2007; 88(2):179-187.

Ray R, Jepson C, Wileyto EP, Dahl J, Patterson F, Rukstalis M, Pinto A, Berrettini W, Lerman C. Genetic variation in mu opioid receptor interacting protein and smoking cessation in a nicotine replacement therapy trial. Nicotine and Tobacco Research, 2007; 9(11)1237-1241.

Ray R, Jepson C, Wileyto EP, Patterson F, Strasser AA, Rukstalis M, Perkins K, Blendy J, Lerman C. CREB1 haplotypes and the relative reinforcing value of nicotine. Molecular Psychiatry, 2007; 12(7):615-617.

Ray R, Schnoll RA, Lerman C. Pharmacogenetics and smoking cessation with nicotine replacement therapy. CNS Drugs, 2007; 21(7) 525-533.

Schnoll RA, Patterson F, Lerman C. Treating tobacco dependence in women. Journal of Women’s Health, 2007; 16(8):1211-1218.

Schnoll RA, Wileyto EP, Hornik R, Schiller J, Lerman C. Spiral computed tomography and lung cancer: science, the media, and public opinion. Journal of Clinical Oncology, 2007; 25(36):5695-5697.

Schnoll RA, Johnson T, Lerma, C. Genetics and smoking behavior. Current Psychiatry Reports, 2007; 9, 349-357.

Strasser AA, Malaiyandi V, Hoffmann E, Tyndale RF, Lerman C. An association of CYP2A6 genotype and smoking topography. Nicotine and Tobacco Research, 2007; 9(4):511-518.

Strasser AA, Lerman C, Sanborn PM, Pickworth WB, Feldman EA. New lower nicotine cigarettes produce compensatory smoking and increased carbon monoxide exposure. Drug and Alcohol Dependence, 2007; 86(2-3):294-300.

Wang Z, Faith M, Patterson F, Tang K, Kerrin K, Wileyto EP, Detre JA, Lerman C. Neural substrates of abstinence-induced cigarette cravings in chronic smokers. Journal of Neuroscience, 2007;27:14030-14040.

Waters AJ, Heishman SJ, Lerman C, Pickworth W. Enhanced identification of smoking-related words during the attentional blink in smokers. Addictive Behaviors, 2007; 32(12):3077-3082.

Year 2006

Audrain-McGovern J, Rodriguez D, Patel V, Faith MS, Rodgers K, Cuevas J. How do psychological factors influence adolescent smoking progression? The evidence for indirect effects through tobacco advertising receptivity. Pediatrics, 2006;117(4):1216-1225.

Audrain-McGovern J, Rodriguez D, Tercyak KP, Neuner G, Moss HB. The impact of self-control indices on peer smoking and adolescent smoking progression. Journal of Pediatric Psychology, 2006; 31(2):139-151.

Audrain-McGovern J, Rodriguez D, Wileyto EP, Schmitz KH, Shields PG. Effect of team sport participation on genetic predisposition to adolescent smoking progression. Archives of General Psychiatry, 2006; 63(4):433-441.

Dahl JP, Jepson C, Levenson R, Wileyto EP, Patterson F, Berrettini WH, Lerman C. Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. Pharmacogenomics Journal, 2006; 6(3):194-199.

Davis JA, Gould TJ. The effects of DHBE and MLA on nicotine-induced enhancement of contextual fear conditioning in C57BL/6 mice. Psychopharmacology, 2006; 184(3-4):345-352.

Davis JA, Porter J, Gould TJ. Nicotine enhances both foreground and background contextual fear conditioning. Neuroscience Letters, 2006; 394(3):202-205.

Gould, TJ. Nicotine and hippocampus-dependent learning: implications for addiction. Molecular Neurobiology, 2006; 34(2):93-107.

Hu J, Redden DT, Berrettini WH, Shields PG, Restine SL, Pinto A, Lerman C, Allison DB. No evidence for a major role of polymorphisms during bupropion treatment. Obesity, 2006; 14(11):1863-1867.

Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, Kaufmann V, Restine S, Hawk L, Niaura R, Berrettini W. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology, 2006; 31(1):231-242.

Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, Benowitz N. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clinical Pharmacology & Therapeutics, 2006; 79(6):600-608.

Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Molecular Psychiatry, 2006; 11(4):400-409.

Munafò MR, Johnstone EC, Wileyto EP, Shields PG, Elliot KM, Lerman C. Lack of association of 5‑HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiology Biomarkers and Prevention, 2006; 15(2):398-400.

Munafò MR, Lerman C. Can pharmacogenetics help smokers quit? Pharmacogenomics, 2006; 7(8):1137-1140.

Perkins KA, Doyle T, Ciccocioppo M, Conklin C, Sayette M, Caggiula A. Sex differences in the influence of nicotine dose instructions on the reinforcing and self-reported rewarding effects of smoking. Psychopharmacology, 2006; 184(3-4):600-607.

Perkins KA, Stitzer M, Lerman C. Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology, 2006; 184(3-4):628-636.

Ray R, Jepson C, Patterson F, Strasser A, Rukstalis M, Perkins K, Lynch KG, O’Malley S, Berrettini WH, Lerman C. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology, 2006; 188(3):355-363.

Schnoll RA, Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opinion on Emerging Drugs, 2006; 11(3):429-444.

Schnoll RA, Rukstalis M, Wileyto P, Shields AE. Smoking cessation treatment by primary care physicians: an update and call for physician training. American Journal of Preventive Medicine, 2006; 31(3):233-239.

Shadel WG, Lerman C, Cappella J, Strasser AA, Pinto A, Hornik R. Evaluating smokers’ reactions to advertising for new lower nicotine Quest cigarettes. Psychology of Addictive Behaviors, 2006; 20(1):80-84.

Strasser AA, O'Connor RJ, Mooney ME, Wileyto EP. Digital image analysis of cigarette filter stains as an indicator of compensatory smoking. Cancer Epidemiology Biomarkers and Prevention, 2006; 15(12):2565-2569.

Volpp KG, Gurmankin Levy A, Asch DA, Berlin JA, Murphy JJ, Gomez A, Sox H, Zhu J, Lerman Co. A randomized controlled trial of financial incentives for smoking cessation. Cancer Epidemiology Biomarkers and Prevention, 2006; 15(1):12-18.

Year 2005

Berrettini WH, Lerman C. Pharmacotherapy and pharmacogenetics of nicotine dependence. American Journal of Psychiatry, 2005; 162(8):1441-1451.

Blendy JA, Strasser A, Walters CL, Perkins KA, Patterson F, Berkowitz R, Lerman C. Reduced nicotine reward in obesity: cross comparison in human and mouse. Psychopharmacology, 2005; 180(2):306-315.

Cappella JN, Lerman C, Romantan A, Baruh L. News about genetics and smoking: priming, family smoking history, and news story credibility effects on inferring genetic susceptibility to tobacco addiction. Communication Research, 2005; 32(4):478-502.

Carson NJ, Rodriguez D, Audrain-McGovern J. Investigation of mechanisms linking media exposure to smoking in high school students. Preventive Medicine, 2005; 41(2):511-520.

Colilla S, Lerman C, Shields PG, Jepson C, Rukstalis M, Berlin J, DeMichele A, Bunin G, Strom BL, Rebbeck TR. Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenetics and Genomics, 2005; 15(6):393-398.

Davis JA, James JR, Siegel SJ, Gould TJ. Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice. The Journal of Neuroscience, 2005; 25(38):8708-8713.

Furberg H, Bulik CM, Lerman C, Lichtenstein P, Pedersen NL, Sullivan PF. Is Swedish snus associated with smoking initiation or smoking cessation? Tobacco Control, 2005; 14(6):422-424.

Furberg H, Sullivan PF, Maes H, Prescott CA, Lerman C, Bulik C, Kendler KS. The types of regular cigarette smokers: a latent class analysis. Nicotine and Tobacco Research, 2005; 7(3):351-360.

Gould TJ, Rukstalis M, Lewis MC. Atomoxetine and nicotine enhance prepulse inhibition of acoustic startle in C57BL/6 mice. Neuroscience Letters, 2005; 377(2):85-90.

Lerman C, Patterson F, Berrettini W. Treating tobacco dependence: state of the science and new directions. Journal of Clinical Oncology, 2005; 23(2):311-323.

Munafo MR, Lerman C, Niaura R, Shields AE, Swan GE. Smoking cessation treatment: pharmacogenetic assessment. Current Opinion in Molecular Therapeutics, 2005; 7(3):202-208.

Munafo MR, Shields AE, Berrettini WH, Patterson F, Lerman C. Pharmacogenetics and nicotine addiction. Pharmacogenomics, 2005; 6(3):211-223.

Munafo MR, Wileyto EP, Flint J. Response to Manly: statistical stringency in tests of genetic association - implications of sample size and study design. Trends in Genetics, 2005; 21(5):269-271.

Redden DT, Shields PG, Epstein L, Wileyto EP, Zakharkin SO, Allison DB, Lerman C. Catechol-O-methyl-transferase functional polymorphism and nicotine dependence: an evaluation of nonreplicated results. Cancer Epidemiology Biomarkers and Prevention, 2005; 14(6):1384-1389.

Roberts KH, Munafo MR, Rodriguez D, Drury M, Murphy MF, Neale RE, Nettle D. Longitudinal analysis of the effect of prenatal nicotine exposure on subsequent smoking behaviour of offspring. Nicotine and Tobacco Research, 2005; 7(5):801-808.

Rodriguez D, Audrain-McGovern J. Physical activity, global physical self-concept and adolescent smoking. Annals of Behavioral Medicine, 2005; 30(3):251-259.

Rodriguez D, Moss HB, Audrain-McGovern J. Developmental heterogeneity in adolescent depressive symptoms: associations with smoking behavior. Psychosomatic Medicine, 2005; 67(2):200-210.

Rukstalis M, Jepson C, Patterson F, Lerman C. Increases in hyperactive-impulsive symptoms predict relapse among smokers in nicotine replacement therapy. Journal of Substance Abuse Treatment, 2005; 28(4):297-304.

Rukstalis M, Jepson C, Strasser A, Lynch KG, Perkins K, Patterson F, Lerman C. Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology, 2005; 180(1):41-48.

Shields AE, Blumenthal D, Weiss KB, Comstock CB, Currivan D, Lerman C. Barriers to translating emerging genetic research on smoking into clinical practice: perspectives of primary care physicians. Journal of General Internal Medicine, 2005; 20(2):131-138.

Shields AE, Fortun M, Hammonds EM, King PA, Lerman C, Rapp R, Sullivan PF. The use of race variables in genetic studies of complex traits and the goal of reducing health disparities: a transdisciplinary perspective. American Psychologist, 2005; 60(1):77-103.

Siegel SJ, Maxwell CR, Majumdar S, Treif DF, Lerman C, Gur RE, Kanes SJ, Liang Y. Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials. Neuroscience, 2005; 133(3):729-738.

Strasser AA, Kaufmann V, Jepson C, Perkins KA, Pickworth WB, Wileyto EP, Rukstalis M, Audrain-McGovern J, Lerman C. Effects of different nicotine replacement therapies on postcessation psychological responses. Addictive Behaviors, 2005; 30(1):9-17.

Strasser AA, Ashare RL, Koslowski LT, Pickworth WB. The effect of filter vent blocking and smoking topography on carbon monoxide levels in smokers. Pharmacology, Biochemistry and Behavior, 2005; 82(2):320-329.

Walters CL, Cleck JN, Kuo YC, Blendy JA. Mu opiate receptor and CREB activation are required for nicotine reward. Neuron, 2005; 46(6):933-943.

Wileyto EP, Patterson F, Niaura R, Epstein LH, Brown RA, Audrain-McGovern J, Hawk LW, Jr., Lerman C. Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. Nicotine and Tobacco Research, 2005; 7(2):257-268.

Year 2004

Audrain-McGovern J, Rodriguez D, Tercyak KP, Cuevas J, Rodgers K, Patterson F. Identifying and characterizing adolescent smoking trajectories. Cancer Epidemiology. Biomarkers and Prevention, 2004; 13(12):2023-2034.

Audrain-McGovern J, Lerman C, Wileyto EP, Rodriguez D, Shields PG. Interacting effects of genetic predisposition and depression on adolescent smoking progression. American Journal of Psychiatry, 2004; 161(7):1224-1230.

Audrain-McGovern J, Rodriguez D, Tercyak KP, Epstein LH, Goldman P, Wileyto EP. Applying a behavioral economic framework to understanding adolescent smoking. Psychology of Addictive Behaviors, 2004; 18(1):64-73.

Collins BN, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Kaufmann V, Pinto A, Hawk L, Niaura R, Epstein LH, Lerman C. Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine and Tobacco Research, 2004; 6(1):27-37.

Epstein LH, Wright SM, Paluch RA, Leddy J, Hawk LW, Jr., Jaroni JL, Saad FG, Crystal-Mansour S, Lerman C. Food hedonics and reinforcement as determinants of laboratory food intake in smokers. Physiology and Behavior, 2004; 81(3):511-517.

Epstein LH, Wright SM, Paluch RA, Leddy JJ, Hank, LW, Jr., Jaroni JL, Sand FG, Crystal-Mansour S., Shields PG, Lerman C. The relationship between food reinforcement and dopamine genotypes and its effect on food intake in smokers. American Journal of Clinical Nutrition, 2004; 80(1)82-88.

Erblich J, Lerman C, Self DW, Diaz GA, Bovbjerg DH. Stress-induced cigarette craving: effects of the DRD2 Taql RFLP and SLC6A3 VNTR polymorphisms. The Pharmacogenomics Journal, 2004; 4(2):102-109.

Jaroni J, Wright SM, Lerman C, Epstein LH. Relationship between education and delay discounting in smokers. Addictive Behaviors, 2004; 29(6):1171-1175.

Kaufmann V, Jepson C, Rukstalis M, Perkins K, Audrain-McGovern J, Lerman C. Subjective effects of an initial dose of nicotine nasal spray predict treatment outcome. Psychopharmacology, 2004; 172(3):271-276.

Lee EM, Malson JL, Moolchan ET, Pickworth WB. Quantitative comparisons between a nicotine delivery device (Eclipse) and conventional cigarette smoking. Nicotine and Tobacco Research, 2004; 6(1):95-102.

Lerman C, Berrettini W, Pinto A, Patterson F, Crystal-Mansour S, Wileyto EP, Restine SL, Leonard DG, Shields PG, Epstein LH. Changes in food reward following smoking cessation: a pharmacogenetic investigation. Psychopharmacology, 2004; 174(4):571-577.

Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, Benowitz N. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Annals of Internal Medicine, 2004; 140(6):426-433.

Lerman C, Niaura R, Collins BN, Wileyto EP, Audrain-McGovern J, Pinto A, Hawk L, Epstein LH. Effects of bupropion on depression symptoms in a smoking cessation clinical trial. Psychology of Addictive Behaviors, 2004; 18(4):362-366.

Lerman C, Shields AE. Genetic testing for cancer susceptibility: the promise and the pitfalls. Nature Reviews Cancer, 2004; 4(3):235-241.

Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, Shields PG, Kaufmann V, Redden D, Benowitz N, Berrettini WH. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. The Pharmacogenomics Journal, 2004; 4(3):184-192.

Lessov CN, Swan GE, Ring HZ, Khroyan TV, Lerman C. Genetics and drug use as a complex phenotype. Substance Use and Misuse, 2004; 39(10-12):1515-1569.

Patterson F, Lerman C, Kaufmann VG, Neuner GA, Audrain-McGovern J. Cigarette smoking practices among American college students: review and future directions. Journal of American College Health, 2004; 52(5):203-210.

Perkins KA, Lerman C, Kennan J, Fonte C, Coddington S. Rate of nicotine onset from nicotine replacement and acute responses in smokers. Nicotine and Tobacco Research, 2004; 6(3):501-507.

Rodriguez D, Audrain-McGovern J. Team sport participation and smoking: analysis with general growth mixture modeling. Journal of Pediatric Psychology, 2004; 29(4):299-308.

Rodriguez D, Audrain-McGovern J. Construct validity analysis of the early smoking experience questionnaire for adolescents. Addictive Behaviors, 2004; 29(5):1053-1057.

Shields A, Lerman C, Sullivan P. Translating emerging research on the genetics of smoking into clinical practice: ethical and social considerations. Nicotine and Tobacco Research, 2004; 6(4):675-688.

Strasser A, Pickworth WB, Patterson F, Lerman C. Smoking topography predicts abstinence following treatment with nicotine replacement therapy. Cancer Epidemiology, Biomarkers and Prevention, 2004; 13(11 Pt 1):1800-1804.

Wileyto EP, Audrain-McGovern J, Epstein LH, Lerman C. Using logistic regression to estimate delay-discounting functions. Behavior Research Methods, Instrumentation and Computers, 2004; 36(1):41-51.

Wileyto EP, Patterson F, Niaura R, Epstein L, Brown R, Audrain-McGovern J, Hawk L, Lerman C. Do small lapses predict relapse to smoking behavior under bupropion treatment. Nicotine and Tobacco Research, 2004; 6(2):357-366.

Year 2003

Audrain-McGovern J, Tercyak, KP, Shields AE, Bush A, Espinel CF, Lerman C. Which adolescents are most receptive to tobacco industry marketing? Implications for counter-advertising campaigns. Health Communication, 2003; 15(4):499-513.

Audrain-McGovern J, Rodriguez D, Moss HB. Smoking progression and physical activity. Cancer Epidemiology, Biomarkers and Prevention, 2003; 12(11 Pt 1):1121-1129.

Baker TB, Hatsukami DK, Lerman C, O’Malley SS, Shields AE, Fiore MC. Transdisciplinary science applied to the evaluation of treatments for tobacco use. Nicotine and Tobacco Research, 2003; 5 Suppl 1:S89-S99.

Dallery J, Houtsmuller EJ, Pickworth WB, Stitzer M. Effects of cigarette nicotine content and smoking pace on subsequent craving and smoking. Psychopharmacology, 2003; 165(2):172‑180.

Epstein LH, Richards JB, Saad FG, Paluch RA, Roemmich JN, Lerman C. Comparison between two measures of delayed discounting in smokers. Experimental and Clinical Psychopharmacology, 2003; 11(2):131-138.

Jamner LD, Whalen CK, Loughlin SE, Mermelstein R, Audrain-McGovern J, Krishnan-Sarin S, Worden JK, Leslie FM. Tobacco use across the formative years: a road map to developmental vulnerabilities. Nicotine and Tobacco Research, 2003; 5 Suppl 1:S71-S87.

Lee EM, Malson JL, Waters AJ, Moolchan ET, Pickworth WB. Smoking topography: reliability and validity in dependent smokers. Nicotine and Tobacco Research, 2003; 5(5):673-679.

Lerman C, Berrettini W. Elucidating the role of genetic factors in smoking behavior and nicotine dependence. American Journal of Medical Genetics (Neuropsychiatric Genetics), 2003; 118(1):48-54.

Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH, Jr., Pinto A, Kucharski S, Krishnan S, Niaura R, Epstein L. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychology,2003; 22(5):541-548.

Malson JL, Lee EM, Murty R, Moolchan ET, Pickworth WB. Clove cigarette smoking: biochemical, physiological, and subjective effects. Pharmacology, Biochemistry and Behavior, 2003; 74(3):739-745.

Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology, 2003; 45(1):122-132.

Morgan GD, Kobus K, Gerlach KK, Neighbors C, Lerman C, Abrams DB, Rimer BK. Facilitating transdisciplinary research: the experience of the transdisciplinary tobacco use research centers. Nicotine and Tobacco Research, 2003; 5 Suppl 1:S11-S19.

Nash JM, Collins BN, Loughlin SE, Solbrig M, Harvey R, Krishnan-Sarin S, Unger J, Miner C, Rukstalis M, Shenassa E, Dube C, Spirito A. Training the transdisciplinary scientist: a general framework applied to tobacco use behavior. Nicotine and Tobacco Research, 2003 5 Suppl 1:S41-53.

Patterson F, Benowitz N, Shields P, Kaufmann V, Jepson C, Wileyto P, Kucharski S, Lerman C. Individual differences in nicotine intake per cigarette. Cancer, Epidemiology, Biomarkers and Prevention, 2003; 12(5):468-471.

Patterson F, Jepson C, Kaufmann V, Rukstalis M, Audrain-McGovern J, Kucharski S, Lerman C. Predictors of attendance in a randomized clinical trial of nicotine replacement therapy with behavioral counseling. Drug and Alcohol Dependence, 2003; 72(2):123‑131.

Pickworth WB, O'Hare ED, Fant RV, Moolchan ET. EEG effects of conventional and denicotinized cigarettes in a spaced smoking paradigm. Brain and Cognition, 2003; 53(1):75-81.

Shenassa ED, McCaffery JM, Swan GE, Khroyan TV, Shakib S, Lerman C, Lyons M, Mouttapa M, Niaura RS, Buka SL, Leslie F, Santangelo SL. Intergenerational transmission of tobacco use and dependence: a transdisciplinary perspective. Nicotine and Tobacco Research, 2003; 5 Suppl 1:S55-S69.

Tercyak KP, Audrain-McGovern J. Personality differences associated with smoking experimentation among adolescents with and without comorbid symptoms of ADHD. Substance Use and Misuse, 2003; 38(14):1953-1970.

Unger JB, Cruz T, Shakib S, Mock J, Shields A, Baezconde-Garbanati L, Palmer P, Cruz JD, Edsall E, Gritz ER, Glynn T, Johnson CA. Exploring the cultural context of tobacco use: a transdisciplinary framework. Nicotine and Tobacco Research, 2003; 5Suppl1:S101-S117.

Year 2002

Audrain J, Tercyak KP, Goldman P, Bush A. Recruiting adolescents into genetic studies of smoking behavior. Cancer Epidemiology, Biomarkers and Prevention, 2002; 11(3):249-252.

Epstein LH, Jaroni JL, Paluch RA, Leddy JJ, Vahue HE, Hawk L, Wileyto EP, Shields PG, Lerman C. Dopamine transporter genotype as a risk factor for obesity in smokers. Obesity Research, 2002; 10(12):1232-1240.

Hemminki K, Shields PG. Skilled use of DNA polymorphisms as a tool for polygenic cancers. Carcinogenesis, 2002; 23(3):379-380.

Lerman C, Croyle RT, Tercayk KP, Hamann H. Genetic testing: psychological aspects and implications. Journal of Consulting and Clinical Psychology, 2002; 70(3):784-797.

Lerman C, Niaura R. Applying genetic approaches to the treatment of nicotine dependence. Oncogene, 2002; 21(48):7412-7420.

Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, Niaura R, Epstein L. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug and Alcohol Dependence, 2002; 67(2):219-223.

Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, Krishnan S, Niaura R, Epstein L. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics, 2002; 12(8):627-634.

Lerman C, Swan GE. Non-replication of genetic association studies: is DAT all, folks? Nicotine and Tobacco Research, 2002; 4(3):247-249.

Malson JL, Lee EM, Moolchan ET, Pickworth WB. Nicotine delivery from smoking bidis and an additive-free cigarette. Nicotine and Tobacco Research, 2002; 4(4):485-490.

Malson JL, Pickworth WB. Bidis-hand-rolled, Indian cigarettes: effects on physiological, biochemical and subjective measures. Pharmacology, Biochemistry, and Behavior, 2002; 72(1-2):443-447.

Shields PG. Molecular epidemiology of smoking and lung cancer. Oncogene, 2002; 21(45):6870-6876.

Shields PG. Tobacco smoking, harm reduction, and biomarkers. Journal of the National Cancer Institute, 2002; 94(19):1435-1444.

Tercyak KP, Audrain J. Psychosocial correlates of alternative tobacco product use in early adolescence. Preventive Medicine, 2002; 35(2):193-198.

Tercyak KP, Goldman P, Smith A, Audrain J. Interacting effects of depression and tobacco advertising receptivity on adolescent smoking. Journal of Pediatric Psychology, 2002; 27(2):145-154.

Tercyak KP, Lerman C, Audrain J. Association of attention-deficit/hyperactivity disorder symptoms with levels of cigarette smoking in a community sample of adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 2002; 41(7):799‑805.

Wilfond BS, Geller G, Lerman C, Audrain-McGovern J, Shields AE. Ethical issues in conducting behavioral genetics research: the case of smoking prevention trials among adolescents. Journal of Health Care Law and Policy, 2002; 6(1):73-88.

Year 2000-2001

Caporaso NE, Lerman C, Audrain J, Boyd NR, Main D, Issaq HJ, Utermahlan B, Falk RT, Shields P. Nicotine metabolism and CYP2D6 phenotype in smokers. Cancer Epidemiology, Biomarkers and Prevention, 2001; 10(3):261-263.

Lerman C, Audrain J, Tercyak K, Hawk LW Jr., Bush A, Crystal-Mansour S, Rose C, Niaura R, Epstein LH. Attention-Deficit Hyperactivity Disorder (ADHD) symptoms and smoking patterns among participants in a smoking-cessation program. Nicotine and Tobacco Research, 2001; 3(4):353-359.

Lerman C, Caporaso NE, Bush A, Zheng YL, Audrain J, Main D, Shields PG. Tryptophanhydroxylase gene variant and smoking behavior. American Journal of Medical Genetics (Neuropsychiatric Genetics), 2001; 105(6)518-520.

Lerman C, Caporaso NE, Audrain J, Main D, Boyd NR, Shields PG. Interacting effects of the serotonin transporter gene and neuroticism in smoking practices and nicotine dependence. Molecular Psychiatry, 2000; 5(2):189-92

Malson JL, Sims K, Murty R, Pickworth WB. Comparison of the nicotine content of tobacco used in bidis and conventional cigarettes. Tobacco Control, 2001; 10(2):181‑183.

Marteau TM, Lerman C. Genetic risk and behavioural change. British Medical Journal, 2001; 322(7293):1056-1059.